Market Access Views & Analysis

Views & Analysis

Debates & Insight

Paid medicine. Cost of treatment. Isolated 3D image

Pricing and Market Access Outlook 2018

This year’s edition of Pricing and Market Access Outlook, our first as IQVIA, identifies a trend towards models that reward value and outcomes.

Views & Analysis

Rethinking the communication of clinical trial results

If clinical trial results were more quickly and openly accessible, medical improvements would be implemented more swiftly too. So what can be done to ease this process?

Views & Analysis

Executives walking inside gears at sea at dawn demonstrate the power of cooperation and synergy.

The Cancer Vanguard: NHS and pharma partnership improves pat...

The Pharma Challenge saw Amgen, Merck, IQVIA and uMotif collaborate with the NHS on a range of projects to improve care for cancer patients.

Views & Analysis

NHS England takes charge on market access

Today sees patients gain full NHS access to breast cancer drug Perjeta, a full six years on from its initial review by NICE.

Views & Analysis

Patient involvement in HTA

Considering the essential role of patient experience in HTA and the role of pharma.

Debates & Insight

Pricing and market access – facts versus fiction

‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.

Pricing and Market Access Outlook 2018

Rethinking the communication of clinical trial results

The Cancer Vanguard: NHS and pharma partnership improves pat...

NHS England takes charge on market access

Patient involvement in HTA

Pricing and market access – facts versus fiction

Roche, Viking, and Syntis showcase obesity drug candidates

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks